North Chelmsford, MA, United States of America

John T Santini, Jr

This inventor holds 49 USPTO granted patents and 8 published patent applications and 2 EPO patents, primarily in Drug Delivery Devices. Top assignees: Microchips, Inc., Massachusetts Institute of Technology, On Demand Therapeutics, Inc.. Active years: 1998-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John T Santini, Jr. Retrieved from https://idiyas.com/inventor/john-t-santini-jr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 49 

% Patents Active = 42.9

 

Average Co-Inventor Count = 3.6

ph-index = 28

Forward Citations = 6,358(Granted Patents)


Location History:

  • Jackson, MI (US) (1998 - 2000)
  • Bedford, MA (US) (2008)
  • Belmont, MA (US) (2002 - 2011)
  • Chelmsford, MA (US) (2009 - 2011)
  • North Chelmsford, MA (US) (2004 - 2014)

Company Filing History:


Years Active: 1998-2014

Loading Chart...
Loading Chart...
Areas of Expertise:
Laser-Activated Delivery
Electrochemical Biosensors
Implantable Devices
Controlled Release
Drug Reservoirs
Microchip Devices
Osmotic Release
Neural Stimulation
Transdermal Delivery
Medical Sensors
Flexible Devices
Hermetically Sealed
49 patents (USPTO):Explore Patents

Title: The Innovative Contributions of John T. Santini, Jr.

Introduction: John T. Santini, Jr. is a notable inventor based in North Chelmsford, Massachusetts, with an impressive portfolio that boasts 49 patents. His work primarily revolves around medical devices and drug delivery systems, demonstrating a keen focus on improving therapeutic methods through innovative technology.

Latest Patents: Among Santini's latest patents are groundbreaking inventions that enhance drug delivery devices. One such patent describes a low-permeability, laser-activated drug delivery device designed to be implantable. This device utilizes multiple reservoir elements to contain active pharmaceutical ingredients, featuring a first shell element that forms a low-permeability barrier. This element absorbs laser irradiation, causing a breach and releasing the stored drug. Additionally, there is a second shell element, also a low-permeability barrier, that contains a different active pharmaceutical ingredient. The combination ensures precise drug delivery within the body.

Another significant patent focuses on visual indication of the rupture of a drug reservoir in an implantable medical device. This innovation provides methods for visualizing the opening of drug reservoirs, particularly useful in devices placed within the vitreous of an eye. By implanting a drug delivery device with several reservoirs, each containing a therapeutic agent and a visual marker, healthcare providers can confirm the release of the therapeutic agent by observing the marker’s presence.

Career Highlights: Santini has worked with prominent organizations, including Microchips, Inc. and the Massachusetts Institute of Technology (MIT). His experiences in these institutions play a crucial role in shaping his inventive capabilities and outcomes in the field of medical technology.

Collaborations: Throughout his career, Santini has collaborated with renowned colleagues, including Michael John Cima and Norman F. Sheppard, Jr. These partnerships have likely contributed to his success and the effective translation of innovative ideas into patented technologies.

Conclusion: John T. Santini, Jr.’s contributions to the fields of medical devices and drug delivery are marked by his 49 patents, reflecting his commitment to innovation and healthcare advancement. His pioneering work continues to influence the medical technology landscape, showcasing the profound impact that dedicated inventors have on improving patient care through inventive solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…